Analysis Tools|
Allele Symbol Allele Name Allele ID |
Gt(ROSA)26Sortm1(rtTA)Awu targeted mutation 1, Anton Wutz MGI:3664736 |
||||||||||||||||||||||||||||
| Summary |
6 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• hypoxic primary tubular epithelial cells from doxycycline treated mice fails to migrate unlike similarly treated cells from Hif1atm3Rsjo/Hif1atm3Rsjo Gt(ROSA)26Sortm1(rtTA)Awu/Gt(ROSA)26Sor+ mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• uninduced mice are normal and fertile
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• uninduced mice are normal and fertile
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E0.5 exhibit severe developmental defect at E7.5 compared with control mice
• however, no developmental defect is observed when the allele is maternally inherited or when doxycycline treated blastocysts with paternally inherited Tsixtm1.1Awu are transplanted into wild-type recipients
|
|
|
• when Tsixtm1.1Awu is inherited maternally, female mice treated with doxycycline from E6.5 exhibit reduced density of fetal capillaries in the placental labyrinth compared with control mice
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E6.5 exhibit a severe defect in fetal capillaries compared with control mice
|
|
|
• in severely affected female mice treated with doxycycline from E6.5 when Tsixtm1.1Awu is inherited paternally
|
|
|
• at E13.5 in female mice treated with doxycycline from E6.5 or E7.5 when Tsixtm1.1Awu is inherited paternally
• mild at E13.5 in female mice treated with doxycycline from E8.5 when Tsixtm1.1Awu is inherited paternally
• however, female mice treated with doxycycline from E9.5 exhibit normal placenta size at E13.5 when the allele is inherited paternally
|
|
|
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E6.5 exhibit a severe defect in all trophoblast cell types compared with control mice
|
|
|
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E6.5 exhibit overabundant and massively enlarged compared to in control mice
|
|
|
• in severely affected female mice treated with doxycycline from E6.5 when Tsixtm1.1Awu is inherited paternally
|
|
|
• absent in severely affected female mice treated with doxycycline from E6.5 when Tsixtm1.1Awu is inherited paternally
|
|
|
• increased in female mice treated with doxycycline from E6.5 when Tsixtm1.1Awu is inherited paternally
|
|
|
• in female mice treated with doxycycline from E6.5 when Tsixtm1.1Awu is inherited paternally
|
|
|
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E0.5 fail to imprint and inactivated the paternal X chromosome unlike in control mice
|
|
|
• when Tsixtm1.1Awu is inherited maternally, female mice treated with doxycycline from E6.5 exhibit reduced density of fetal capillaries in the placental labyrinth compared with control mice
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E6.5 exhibit a severe defect in fetal capillaries compared with control mice
|
|
|
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E0.5 exhibit severe developmental defect at E7.5 compared with control mice
• however, no developmental defect is observed when the allele is maternally inherited or when doxycycline treated blastocysts with paternally inherited Tsixtm1.1Awu are transplanted into wild-type recipients
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• in mice where doxycycline treatment begins at 4 weeks of age most mice die between 5 to 6 weeks after initiation of treatment with none surviving more than 10 weeks
|
|
|
• mice exposed to doxycycline for 4 days beginning at E12.5 die within 1 day after birth probably as a result of hematopoietic failure
|
|
|
• treatment with doxycycline before E9.5 results in death of the embryo within 3 days
|
|
|
• 6 weeks after initiation of doxycycline treatment (started at 4 weeks of age)the thymus is severely reduced in size or absent
|
|
|
• all T cell subsets rapidly decline after initiation of doxycycline treatment (started at 4 weeks of age) producing a strong reduction in overall cellularity
|
|
|
• all T cell subsets rapidly decline in the thymus after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• doxycycline treatment initiated at 4 weeks of age results in rapid loss of lineage committed immature cells; however populations of progenitor cells that include hematopoietic stem cells and pre-pro B cells are expanded 20- and 10-fold, respectively, after 2 weeks of treatment
|
|
|
• a transient expansion of Ter119+ erythroid cells is seen 7 days after initiation of doxycycline treatment (started at 4 weeks of age); however erythroid progenitors are significantly reduced at the same time
|
|
|
• severely reduced in the bone marrow at 5 and 7 days after initiation of doxycycline treatment (started at 4 weeks of age)
• however, mature B cells in the bone marrow and spleen are only slightly affected at 5 and 7 days after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• 2-fold reduction in the bone marrow at 5 and 7 days after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• most rapidly lost of the all the T-cell subsets in the thymus after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• reduction in red cell markers indicates loss of red cells in neonates treated for 4 days with doxycycline beginning at E12.5
• seen 4 weeks after initiation of doxycycline treatment when treatment is started at 4 weeks of age
|
|
|
• seen 6 weeks after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• severe decrease in neonates treated for 4 days with doxycycline beginning at E12.5
• in mice where doxycycline treatment begins at 4 weeks of age hematocrit decreases to 1/10 of untreated controls
|
|
|
• doxycycline treatment-induced loss is more gradual than for macrophages but still significant
|
|
|
• nearly absent in the bone marrow at 5 and 7 days after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• most rapidly lost cell type of the myeloid lineages after doxycycline treatment (started at 4 weeks of age)
|
|
|
• treatment with doxycycline at E9.5 results in a severely deformed embryo at E13.5
|
|
|
• 6 weeks after initiation of doxycycline treatment (started at 4 weeks of age)the thymus is severely reduced in size or absent
|
|
|
• all T cell subsets rapidly decline after initiation of doxycycline treatment (started at 4 weeks of age) producing a strong reduction in overall cellularity
|
|
|
• all T cell subsets rapidly decline in the thymus after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• severely reduced in the bone marrow at 5 and 7 days after initiation of doxycycline treatment (started at 4 weeks of age)
• however, mature B cells in the bone marrow and spleen are only slightly affected at 5 and 7 days after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• 2-fold reduction in the bone marrow at 5 and 7 days after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• most rapidly lost of the all the T-cell subsets in the thymus after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• doxycycline treatment-induced loss is more gradual than for macrophages but still significant
|
|
|
• nearly absent in the bone marrow at 5 and 7 days after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• most rapidly lost cell type of the myeloid lineages after doxycycline treatment (started at 4 weeks of age)
|
|
|
• 2 weeks after initiation of doxycycline treatment (started at 4 weeks of age) mice appear weak
|
|
|
• 6 weeks after initiation of doxycycline treatment (started at 4 weeks of age)the thymus is severely reduced in size or absent
|
|
|
• all T cell subsets rapidly decline after initiation of doxycycline treatment (started at 4 weeks of age) producing a strong reduction in overall cellularity
|
|
|
• all T cell subsets rapidly decline in the thymus after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• in mice where doxycycline treatment begins at 4 weeks of age most mice die between 5 to 6 weeks after initiation of treatment with none surviving more than 10 weeks
|
|
|
• 6 weeks after initiation of doxycycline treatment (started at 4 weeks of age)the thymus is severely reduced in size or absent
|
|
|
• seen 6 weeks after initiation of doxycycline treatment (started at 4 weeks of age)
|
|
|
• in mice where doxycycline treatment begins at 4 weeks of age hematocrit decreases to 1/10 of untreated controls
|
|
|
• 6 weeks after initiation of doxycycline treatment (started at 4 weeks of age)the thymus is severely reduced in size or absent
|
|
|
• 2 weeks after initiation of doxycycline treatment (started at 4 weeks of age) mice appear weak
|
|
|
• 6 weeks after initiation of doxycycline treatment (started at 4 weeks of age)the thymus is severely reduced in size or absent
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|
|
||
